Drug Information

Drug General Information
Drug ID
D05XDZ
Former ID
DIB007374
Drug Name
LMT-X
Synonyms
LMT-X; Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 3 [549271]
Company
TauRx Therapeutics Pte Ltd
Target and Pathway
Target(s) Microtubule-associated protein tau Target Info Inhibitor [531616], [550088]
KEGG Pathway MAPK signaling pathway
Alzheimer's disease
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
Pathway Interaction Database LPA receptor mediated events
Reelin signaling pathway
Reactome Caspase-mediated cleavage of cytoskeletal proteins
WikiPathways Notch Signaling Pathway
IL-2 Signaling Pathway
MAPK Signaling Pathway
Copper homeostasis
Kit receptor signaling pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
Alzheimers Disease
Regulation of Microtubule Cytoskeleton
Apoptotic execution phase
IL-5 Signaling Pathway
References
Ref 549271Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
Ref 531616Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
Ref 550088Clinical pipeline report, company report or official report of TauRx.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.